WIKINGO Proyect Systematic Analysis

Tables & Figures.

Proyecto Vikingo September 30, 2016

proyectovikingo@proyectovikingo.es

WIKINGO Project	September 30, 2016	Systematic analysis	2

(٦,	'n	te	n	+0
ı	7) I I	ьe	: 1 1	1.5

\mathbf{List}	of Tables	
1	Participant characteristics	

List of Figures

3

Table 1: Participant characteristics

Age 67.4 (11.5) 77 Sex: Men 54 (70.1%) 77 Tumor level: 77 0-6cm 40 (51.9%) 7-11cm 31 (40.3%) 12-15cm 6 (7.79%) 77 Tumor stage: 77 0 12 (15.6%) 1 17 (22.1%) 11 23 (29.9%) 111 23 (29.9%) 111 25 (32.5%) 171 111	-		[ALL]		
Age 67.4 (11.5) 77 Sex: Men 54 (70.1%) 77 Tumor level: 77 0-6cm 40 (51.9%) 7-11cm 31 (40.3%) 12-15cm 6 (7.79%) Tumor stage: 77 0 12 (15.6%) I 17 (22.1%) II 23 (29.9%) III 23 (29.9%) Neoadjuvant treatment 70 (90.9%) 77 Type of resection: 77 Abdominoperineal resection 22 (28.6%) Anterior resection 45 (58.4%) Hartmann 10 (13.0%) Perforation 4 (5.19%) 77 Invasion circumferential margin 9 (11.7%) 77 Mesorrecto quality: 77 Satisfactory 67 (87.0%) 77 Partial 8 (10.4%) No-satisfactory 2 (2.60%) Recidive 6 (7.79%) 77 Months to recidive 20.0 [12.0;30.0] 77 Metastasis 10 (13.0%) 77 Months to Metastasis 20.0 [12.0;30.0] 77					N
Sex: Men 54 (70.1%) 77 Tumor level: 77 0-6cm 40 (51.9%) 7-11cm 31 (40.3%) 12-15cm 6 (7.79%) Tumor stage: 77 0 12 (15.6%) II 17 (22.1%) III 23 (29.9%) III 25 (32.5%) Neoadjuvant treatment 70 (90.9%) 77 Type of resection: 77 Abdominoperineal resection 45 (58.4%) Hartmann 10 (13.0%) 77 Invasion circumferential margin 9 (11.7%) 77 Mesorrecto quality: 77 Satisfactory 67 (87.0%) 77 Partial 8 (10.4%) 77 Months to recidive 20.0 [12.0;30.0] 77 Metastasis 10 (13.0%) 77 Months to Metastasis 20.0 [12.0;30.0] 77 Exitus 13 (16.9%) 77				67.4 (11.5)	77
Tumor level: 77 0-6cm 40 (51.9%) 7-11cm 31 (40.3%) 12-15cm 6 (7.79%) Tumor stage: 77 0 12 (15.6%) I 17 (22.1%) II 23 (29.9%) III 25 (32.5%) Neoadjuvant treatment 70 (90.9%) 77 Type of resection: 77 Abdominoperineal resection 45 (58.4%) Hartmann 10 (13.0%) Perforation 4 (5.19%) 77 Invasion circumferential margin 9 (11.7%) 77 Mesorrecto quality: 77 Satisfactory 67 (87.0%) 77 Partial 8 (10.4%) 77 No-satisfactory 2 (2.60%) 77 Months to recidive 20.0 [12.0;30.0] 77 Metastasis 10 (13.0%) 77 Months to Metastasis 20.0 [12.0;30.0] 77 Exitus 13 (16.9%) 77		9		` ,	
0-6cm 40 (51.9%) 7-11cm 31 (40.3%) 12-15cm 6 (7.79%) Tumor stage: 77 0 12 (15.6%) I 17 (22.1%) II 23 (29.9%) III 25 (32.5%) Neoadjuvant treatment 70 (90.9%) 77 Type of resection: 77 Abdominoperineal resection 45 (58.4%) Hartmann 10 (13.0%) Perforation 4 (5.19%) 77 Invasion circumferential margin 9 (11.7%) 77 Mesorrecto quality: 77 Satisfactory 67 (87.0%) 77 Partial 8 (10.4%) No-satisfactory 2 (2.60%) Recidive 6 (7.79%) 77 Months to recidive 20.0 [12.0;30.0] 77 Months to Metastasis 20.0 [12.0;30.0] 77 Exitus 13 (16.9%) 77				0 = ((0 = 7 0)	
7-11cm 31 (40.3%) 12-15cm 6 (7.79%) Tumor stage: 77 0 12 (15.6%) I 17 (22.1%) II 23 (29.9%) III 25 (32.5%) Neoadjuvant treatment 70 (90.9%) 77 Type of resection: 77 Abdominoperineal resection 45 (58.4%) Hartmann 10 (13.0%) Perforation 4 (5.19%) 77 Invasion circumferential margin 9 (11.7%) 77 Mesorrecto quality: 77 Satisfactory 67 (87.0%) Partial 8 (10.4%) No-satisfactory 2 (2.60%) Recidive 6 (7.79%) 77 Months to recidive 20.0 [12.0;30.0] 77 Metastasis 10 (13.0%) 77 Months to Metastasis 20.0 [12.0;30.0] 77 Exitus 13 (16.9%) 77				40 (51.9%)	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$				` /	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$,	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$				(77
$\begin{array}{cccccccccccccccccccccccccccccccccccc$		9		12 (15.6%)	
III 23 (29.9%) III 25 (32.5%) Neoadjuvant treatment 70 (90.9%) 77 Type of resection: 77 Abdominoperineal resection 22 (28.6%) Anterior resection 45 (58.4%) Hartmann 10 (13.0%) Perforation 4 (5.19%) 77 Invasion circumferential margin 9 (11.7%) 77 Mesorrecto quality: 77 Satisfactory 67 (87.0%) Partial 8 (10.4%) No-satisfactory 2 (2.60%) Recidive 6 (7.79%) 77 Months to recidive 20.0 [12.0;30.0] 77 Metastasis 10 (13.0%) 77 Months to Metastasis 20.0 [12.0;30.0] 77 Exitus 13 (16.9%) 77		I		` /	
III 25 (32.5%) Neoadjuvant treatment 70 (90.9%) 77 Type of resection: 77 Abdominoperineal resection 22 (28.6%) Anterior resection 45 (58.4%) Hartmann 10 (13.0%) Perforation 4 (5.19%) 77 Invasion circumferential margin 9 (11.7%) 77 Mesorrecto quality: 77 Satisfactory 67 (87.0%) Partial 8 (10.4%) No-satisfactory 2 (2.60%) Recidive 6 (7.79%) 77 Months to recidive 20.0 [12.0;30.0] 77 Metastasis 10 (13.0%) 77 Months to Metastasis 20.0 [12.0;30.0] 77 Exitus 13 (16.9%) 77		II		` /	
Neoadjuvant treatment 70 (90.9%) 77 Type of resection: 77 Abdominoperineal resection 22 (28.6%) Anterior resection 45 (58.4%) Hartmann 10 (13.0%) Perforation 4 (5.19%) 77 Invasion circumferential margin 9 (11.7%) 77 Mesorrecto quality: 77 Satisfactory 67 (87.0%) 67 Partial 8 (10.4%) 8 (10.4%) No-satisfactory 2 (2.60%) 77 Months to recidive 20.0 [12.0;30.0] 77 Metastasis 10 (13.0%) 77 Months to Metastasis 20.0 [12.0;30.0] 77 Exitus 13 (16.9%) 77		III		,	
Type of resection: 77 Abdominoperineal resection 22 (28.6%) Anterior resection 45 (58.4%) Hartmann 10 (13.0%) Perforation 4 (5.19%) 77 Invasion circumferential margin 9 (11.7%) 77 Mesorrecto quality: 77 Satisfactory 67 (87.0%) Partial 8 (10.4%) No-satisfactory 2 (2.60%) Recidive 6 (7.79%) 77 Months to recidive 20.0 [12.0;30.0] 77 Metastasis 10 (13.0%) 77 Months to Metastasis 20.0 [12.0;30.0] 77 Exitus 13 (16.9%) 77		Neoadjuvant treatment		,	77
$\begin{array}{cccccccccccccccccccccccccccccccccccc$,	77
$\begin{array}{cccccccccccccccccccccccccccccccccccc$		Abdominoperineal rese	ection	22 (28.6%)	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$		-		` ,	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$		Hartmann		10 (13.0%)	
Mesorrecto quality: 77 Satisfactory 67 (87.0%) Partial 8 (10.4%) No-satisfactory 2 (2.60%) Recidive 6 (7.79%) 77 Months to recidive 20.0 [12.0;30.0] 77 Metastasis 10 (13.0%) 77 Months to Metastasis 20.0 [12.0;30.0] 77 Exitus 13 (16.9%) 77		Perforation		'	77
Satisfactory 67 (87.0%) Partial 8 (10.4%) No-satisfactory 2 (2.60%) Recidive 6 (7.79%) 77 Months to recidive 20.0 [12.0;30.0] 77 Metastasis 10 (13.0%) 77 Months to Metastasis 20.0 [12.0;30.0] 77 Exitus 13 (16.9%) 77		Invasion circumferential ma	argin	9 (11.7%)	77
$\begin{array}{cccccccccccccccccccccccccccccccccccc$		Mesorrecto quality:	J	,	77
No-satisfactory 2 (2.60%) Recidive 6 (7.79%) 77 Months to recidive 20.0 [12.0;30.0] 77 Metastasis 10 (13.0%) 77 Months to Metastasis 20.0 [12.0;30.0] 77 Exitus 13 (16.9%) 77		Satisfactory		67 (87.0%)	
Recidive 6 (7.79%) 77 Months to recidive 20.0 [12.0;30.0] 77 Metastasis 10 (13.0%) 77 Months to Metastasis 20.0 [12.0;30.0] 77 Exitus 13 (16.9%) 77		Partial		` ′	
Months to recidive 20.0 [12.0;30.0] 77 Metastasis 10 (13.0%) 77 Months to Metastasis 20.0 [12.0;30.0] 77 Exitus 13 (16.9%) 77		No-satisfactory		2(2.60%)	
Metastasis 10 (13.0%) 77 Months to Metastasis 20.0 [12.0;30.0] 77 Exitus 13 (16.9%) 77		Recidive		6 (7.79%)	77
Months to Metastasis 20.0 [12.0;30.0] 77 Exitus 13 (16.9%) 77		Months to recidive	20	0.0 [12.0;30.0]	77
Exitus 13 (16.9%) 77		Metastasis		10 (13.0%)	77
,		Months to Metastasis	20	0.0 [12.0;30.0]	77
Months to exitus 21.0 [13.0;30.0] 77		Exitus		13 (16.9%)	77
		Months to exitus	21	1.0 [13.0;30.0]	77